Alan B Lancz & Associates Inc. Sells 1,800 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Alan B Lancz & Associates Inc. trimmed its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 16.2% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 9,290 shares of the biopharmaceutical company’s stock after selling 1,800 shares during the period. Gilead Sciences makes up about 0.9% of Alan B Lancz & Associates Inc.’s investment portfolio, making the stock its 25th biggest position. Alan B Lancz & Associates Inc.’s holdings in Gilead Sciences were worth $858,000 at the end of the most recent quarter.

Several other institutional investors have also made changes to their positions in GILD. nVerses Capital LLC bought a new stake in shares of Gilead Sciences in the 3rd quarter valued at approximately $25,000. Decker Retirement Planning Inc. acquired a new position in Gilead Sciences during the fourth quarter worth $29,000. Valued Wealth Advisors LLC lifted its holdings in shares of Gilead Sciences by 101.9% during the third quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 161 shares during the period. Strategic Investment Solutions Inc. IL acquired a new stake in shares of Gilead Sciences in the 2nd quarter valued at $33,000. Finally, Friedenthal Financial bought a new stake in shares of Gilead Sciences in the 3rd quarter worth about $50,000. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

GILD has been the subject of several analyst reports. Truist Financial lifted their price target on shares of Gilead Sciences from $83.00 to $97.00 and gave the company a “hold” rating in a report on Friday, November 8th. Daiwa America raised Gilead Sciences to a “hold” rating in a report on Monday, November 18th. BMO Capital Markets increased their price target on Gilead Sciences from $94.00 to $102.00 and gave the stock an “outperform” rating in a research report on Thursday, November 7th. Leerink Partnrs upgraded Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 21st. Finally, Cantor Fitzgerald restated a “neutral” rating and set a $80.00 target price on shares of Gilead Sciences in a report on Wednesday, December 11th. Eleven equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and four have issued a strong buy rating to the company. Based on data from MarketBeat, Gilead Sciences currently has a consensus rating of “Moderate Buy” and an average price target of $97.96.

Insiders Place Their Bets

In other news, CFO Andrew D. Dickinson sold 248,645 shares of the firm’s stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $92.76, for a total transaction of $23,064,310.20. Following the sale, the chief financial officer now owns 138,919 shares of the company’s stock, valued at $12,886,126.44. This trade represents a 64.16 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Jeffrey Bluestone sold 6,788 shares of the business’s stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $91.39, for a total value of $620,355.32. Following the completion of the transaction, the director now owns 8,920 shares of the company’s stock, valued at $815,198.80. This represents a 43.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 456,234 shares of company stock worth $42,130,461. Corporate insiders own 0.16% of the company’s stock.

Gilead Sciences Price Performance

Shares of GILD opened at $93.07 on Friday. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24. The stock has a market cap of $115.99 billion, a P/E ratio of 1,034.11, a price-to-earnings-growth ratio of 1.31 and a beta of 0.18. The stock’s 50-day moving average price is $91.74 and its two-hundred day moving average price is $84.86. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $98.90.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.58 by $0.44. The firm had revenue of $7.55 billion during the quarter, compared to analysts’ expectations of $7.01 billion. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The business’s revenue for the quarter was up 7.0% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.29 earnings per share. On average, equities analysts predict that Gilead Sciences, Inc. will post 4.36 earnings per share for the current year.

Gilead Sciences Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, December 30th. Investors of record on Friday, December 13th were paid a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a yield of 3.31%. The ex-dividend date of this dividend was Friday, December 13th. Gilead Sciences’s payout ratio is presently 3,422.22%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.